CVC sweetens Recordati bid to €53, calls offer ’best and final’
Private equity firm CVC has raised its bid for Italian pharmaceutical company Recordati to €53 per share, declaring it as the "best and final" offer. The new price, an increase from €51.29, values the company at up to €10.52 billion if all 198.5 million shares included in the bid are accepted. This revised offer reflects Recordati's standalone performance and the decreased valuations in Europe's healthcare and specialty pharmaceuticals sectors.
The €53 offer includes the final dividend of €0.71, making the total value €53.71 per share, which is a 16.61% premium compared to Recordati's March 25 closing price. The acceptance period has been extended by six days and will now conclude on Oct. 23 at 5:30 p.m. Italian time. Payment for shares tendered will be made on Nov. 2.
CVC has secured a new bank guarantee for €10.52 billion, replacing the guarantee issued in July. If all conditions are met, CVC may delist Recordati, either through squeeze-out procedures or a merger into the offer vehicle.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
